Artrya Limited · ASX:AYA

Artrya — Q3 FY2025 Earnings Presentation

6 slides from Artrya's earnings presentation, May 1, 2025

  1. Slide 1: April 2025 Quarterly Call

    For personal use only April 2025 Quarterly Call 1 May 2025 1

  2. Slide 2: 3Q FY2025 Quarterly Report

    3Q FY2025 Quarterly Report • Receives milestone Food and Drug Administration (FDA) 510(k) clearance for Salix® Coronary Anatomy for commercial sale in the US. Salix® Coronary Anatomy to be formally launched across hospital systems in the US • Secures three-year commercial contracts with Sonic Health

  3. Slide 3: Pathway to revenue

    Pathway to revenue FDA Roadmap Shortening the pathway to revenue 1. Salix Coronary Anatomy (FDA Cleared) • First revenues from three US partners expected For personal use only in CY25 Cleared on 28 March 2025 • Scale the channel 2. Salix Coronary Plaque (SCP) o Without need of large sales team Estim

  4. Slide 4: SAPPHIRE Study

    SAPPHIRE Study Salix-based Analysis of Plaque to identify Patients at HIgher Risk of Events SAPPHIRE aims to: 1. novel plaque dispersion score (PDS) better risk assessment compared to current For personal use only methods 2. demonstrate that the PDS can be used to appropriately guide medical therapy

  5. Slide 5: Salix is built to target all pillars across the care continuum

    Salix® is built to target all pillars across the care continuum Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. For personal use only Whole Heart Disease Structural Optimised Characterisation Severity Assessment Procedure Detailed Plaque and Dispersion Non-i

  6. Slide 6: Thank You

    For personal use only 6 Thank You

Artrya — Q3 FY2025 Earnings Presentation on 6ix